Potentia Pharmaceuticals Initiates Phase I Clinical Trials to Evaluate its Lead Compound for Age-Related Macular Degeneration
POT-4 is the first complement inhibitor for age-related macular degeneration to enter clinical phase of development
23-Mar-2007 -
Potentia Pharmaceuticals, Inc. announced that it is entering the clinical phase of development for POT-4, its lead drug candidate for the treatment of age-related macular degeneration (AMD). POT-4 is a complement inhibitor, which shuts down the complement activation system that could lead to ...
growth factors
inflammation
inhibitors